IRCCS Ospedale Policlinico San Martino

The ALS Centre at IRCCS Ospedale Policlinico San Martino is the regional referral Centre for ALS and other motor neuron diseases (MNDs) in Liguria, Italy. The structure includes in and out-patient fully equipped clinics staffed by a multidisciplinary team of experts constantly involved in early diagnosis, management and treatment of MNDs. To successfully pursue these objectives the Centre has adopted a multimodal translational research approach integrating clinical, genetic, MRI, cognitive and biofluid markers.

IRCCS Ospedale Policlinico San Martino
Foundation year

1923
Director

Dr. Chiara Gemelli
Principal investigator

Dr. Pilar M. Ferraro, Dr. Chiara Gemelli
Contact information
Address

Largo P. Daneo 3
16132 Genoa, Italy
Contact

Dr. Pilar M. Ferraro, Dr. Chiara Gemelli
Phone

0039 010 555 7290
Email pilarmariaferraro@gmail.com, chiara.gemelli@hsanmartino.it
Website Visit the website

Publications

  • Cabona C, Ferraro PM, Meo G, Roccatagliata L, Schenone A, Inglese M, Villani F, Caponnetto C. Predictors of self-perceived health worsening over COVID-19 emergency in ALS. Neurol Sci. 2021. doi: 10.1007/s10072-020-04997-z.
  • Ferraro PM, Cabona C, Meo G, Rolla-Bigliani C, Castellan L, Pardini M, Inglese M, Caponnetto C, Roccatagliata L. Age at symptom onset influences cortical thinning distribution and survival in Amyotrophic Lateral Sclerosis. Neuroradiology 2021. doi:10.1007/s00234-021-02681-3.
  • Ferraro PM, Campi C, Miceli A, Rolla-Bigliani C, Bauckneht M, Gualco L, Piana M, Marini C, Castellan L, Morbelli S, Caponnetto C, Sambuceti G, Roccatagliata L. 18 F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches. DOI: 10.1016/j.ejro.2022.100394
  • Reply to “Cognition and motor phenotypes in ALS: a retrospective study”. Ferraro PM, Ponzano M, Cillerai M, Signori A, Caponnetto C. Neurol Sci. 2023 Dec;44(12):4531-4533. doi: 10.1007/s10072-023-06976-6. Epub 2023 Jul 31.
  • MND Phenotypes Differentiation: The Role of Multimodal Characterization at the Time of Diagnosis. Meo G, Ferraro PM, Cillerai M, Gemelli C, Cabona C, Zaottini F, Roccatagliata L, Villani F, Schenone A, Caponnetto C.Life (Basel). 2022 Sep 27;12(10):1506. doi: 10.3390/life12101506.
  • Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: a ten year follow up study. Cabona C, Ferraro PM, Scialò C, Bandettini Di Poggio M, Novi G, Gemelli C, Vignolo M, Rao F, Capovilla M, Marogna M, Mandich P, Origone P, Schenone A, Caponnetto C. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Sep 22:1-8. doi: 10.1080/21678421.2023.2260842.
  • Mild behavioral impairment as a potential marker of predementia risk states in motor neuron diseases Ferraro PM, Gervino E, De Maria E, Meo G, Ponzano M, Pardini M, Signori A, Schenone A, Roccatagliata L, Caponnetto C.Eur J Neurol. 2023 Jan;30(1):47-56. doi: 10.1111/ene.15570. Epub 2022 Oct 2.MND Phenotypes Differentiation: The Role of Multimodal Characterization at the Time of Diagnosis

Restricted information

Serving population
Serving population

1.500.000
Patient resources
Population based register

Yes
Clinic based register

Yes
Geographically matched controls

No

Banks

There are no banks for this centre

Research activities
Clinical management research

Yes
Neuro epidemiology

Yes
Neuro physiology

Yes
Neuro imaging

Yes
Neuro psychology

Yes
Neuro pathology

No
Genomics

Yes
Transcriptomics

No
Metabolomics

No

Clinical Trials - Industry sponsored

There are no clinical trials for this centre

Clinical Trials - Investigator initiated

Name Type Patients
Rapamycin Treatment for ALS (RAP-ALS) NCT03359538 Phase II randomized, double-blind, placebo-controlled, multicenter clinical trial 4
The Effect of RNS60 on ALS Biomarkers. NCT03456882 Multicenter, randomized, double-blind, placebo-controlled, parallel group, add-on phase II trial 2
PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN Phase II 2